Logo image of PRAX

PRAXIS PRECISION MEDICINES I (PRAX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRAX - US74006W2070 - Common Stock

272.92 USD
+3.66 (+1.36%)
Last: 12/19/2025, 8:10:41 PM
272.92 USD
0 (0%)
After Hours: 12/19/2025, 8:10:41 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRAX. PRAX was compared to 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRAX as it has an excellent financial health rating, but there are worries on the profitability. PRAX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PRAX has reported negative net income.
In the past year PRAX has reported a negative cash flow from operations.
PRAX had negative earnings in each of the past 5 years.
In the past 5 years PRAX always reported negative operating cash flow.
PRAX Yearly Net Income VS EBIT VS OCF VS FCFPRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -68.88%, PRAX is not doing good in the industry: 61.65% of the companies in the same industry are doing better.
PRAX has a Return On Equity (-79.49%) which is in line with its industry peers.
Industry RankSector Rank
ROA -68.88%
ROE -79.49%
ROIC N/A
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
PRAX Yearly ROA, ROE, ROICPRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRAX Yearly Profit, Operating, Gross MarginsPRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

8

2. Health

2.1 Basic Checks

PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRAX has more shares outstanding
The number of shares outstanding for PRAX has been reduced compared to 5 years ago.
There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRAX Yearly Shares OutstandingPRAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PRAX Yearly Total Debt VS Total AssetsPRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 71.98 indicates that PRAX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 71.98, PRAX belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.
There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 71.98
ROIC/WACCN/A
WACC8.8%
PRAX Yearly LT Debt VS Equity VS FCFPRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

PRAX has a Current Ratio of 5.18. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.18, PRAX is in line with its industry, outperforming 57.33% of the companies in the same industry.
A Quick Ratio of 5.18 indicates that PRAX has no problem at all paying its short term obligations.
With a Quick ratio value of 5.18, PRAX perfoms like the industry average, outperforming 58.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.18
Quick Ratio 5.18
PRAX Yearly Current Assets VS Current LiabilitesPRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PRAX have decreased strongly by -25.24% in the last year.
PRAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 364.98%.
EPS 1Y (TTM)-25.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.18%
Revenue 1Y (TTM)364.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 36.21% on average per year.
PRAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 297.68% yearly.
EPS Next Y-29.57%
EPS Next 2Y-13.95%
EPS Next 3Y4.38%
EPS Next 5Y36.21%
Revenue Next Year-96.83%
Revenue Next 2Y99.73%
Revenue Next 3Y453.53%
Revenue Next 5Y297.68%

3.3 Evolution

PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50 100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRAX. In the last year negative earnings were reported.
Also next year PRAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRAX Price Earnings VS Forward Price EarningsPRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRAX Per share dataPRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.95%
EPS Next 3Y4.38%

More info and screens

0

5. Dividend

5.1 Amount

PRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (12/19/2025, 8:10:41 PM)

After market: 272.92 0 (0%)

272.92

+3.66 (+1.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners89.41%
Inst Owner Change7.82%
Ins Owners0.22%
Ins Owner Change0.38%
Market Cap6.83B
Revenue(TTM)7.46M
Net Income(TTM)-273.04M
Analysts82.86
Price Target410.52 (50.42%)
Short Float %15.18%
Short Ratio2.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.44%
Min EPS beat(2)2.57%
Max EPS beat(2)4.3%
EPS beat(4)2
Avg EPS beat(4)1.21%
Min EPS beat(4)-1.25%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-3.68%
EPS beat(12)7
Avg EPS beat(12)4.13%
EPS beat(16)8
Avg EPS beat(16)0.77%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)409.39%
Min Revenue beat(4)-100%
Max Revenue beat(4)1937.56%
Revenue beat(8)3
Avg Revenue beat(8)301.93%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)58.72%
PT rev (3m)298.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.34%
EPS NY rev (1m)2.75%
EPS NY rev (3m)2.2%
Revenue NQ rev (1m)-8.34%
Revenue NQ rev (3m)-16.67%
Revenue NY rev (1m)-45.46%
Revenue NY rev (3m)-53.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 914.61
P/FCF N/A
P/OCF N/A
P/B 19.87
P/tB 19.87
EV/EBITDA N/A
EPS(TTM)-12.9
EYN/A
EPS(NY)-13.34
Fwd EYN/A
FCF(TTM)-9.15
FCFYN/A
OCF(TTM)-9.15
OCFYN/A
SpS0.3
BVpS13.73
TBVpS13.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.88%
ROE -79.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.18
Quick Ratio 5.18
Altman-Z 71.98
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)38.78%
Cap/Depr(5y)139.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.18%
EPS Next Y-29.57%
EPS Next 2Y-13.95%
EPS Next 3Y4.38%
EPS Next 5Y36.21%
Revenue 1Y (TTM)364.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-96.83%
Revenue Next 2Y99.73%
Revenue Next 3Y453.53%
Revenue Next 5Y297.68%
EBIT growth 1Y-78.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.4%
EBIT Next 3Y4.42%
EBIT Next 5Y26.57%
FCF growth 1Y-97.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-97.16%
OCF growth 3YN/A
OCF growth 5YN/A

PRAXIS PRECISION MEDICINES I / PRAX FAQ

What is the ChartMill fundamental rating of PRAXIS PRECISION MEDICINES I (PRAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRAX.


Can you provide the valuation status for PRAXIS PRECISION MEDICINES I?

ChartMill assigns a valuation rating of 0 / 10 to PRAXIS PRECISION MEDICINES I (PRAX). This can be considered as Overvalued.


What is the profitability of PRAX stock?

PRAXIS PRECISION MEDICINES I (PRAX) has a profitability rating of 0 / 10.


What is the expected EPS growth for PRAXIS PRECISION MEDICINES I (PRAX) stock?

The Earnings per Share (EPS) of PRAXIS PRECISION MEDICINES I (PRAX) is expected to decline by -29.57% in the next year.